The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Barantsevich E.R.

Pavlov First Saint Petersburg State Medical University

Kurushina O.V.

Volgograd State Medical University

Akhmadeeva L.R.

Bashkir State Medical University

Skoromets A.P.

Pavlov First Saint Petersburg State Medical University

Belova A.N.

Privolzhsky Research Medical University

Mendelevich E.G.

Kazan State Medical University

Kovalchuk V.V.

Semashko City Hospital No. 38

Doronina O.B.

Sibneiromed

Barkhatov M.V.

Federal Siberian Scientific and Clinical Center

Kamchatnov P.R.

Pirogov Russian National Research Medical University

Bioregulatory drug Newrexan in the treatment of anxiety and dissomnia. Resolution of the Council of Experts (June 8, 2023)

Authors:

Barantsevich E.R., Kurushina O.V., Akhmadeeva L.R., Skoromets A.P., Belova A.N., Mendelevich E.G., Kovalchuk V.V., Doronina O.B., Barkhatov M.V., Kamchatnov P.R.

More about the authors

Views: 5984

Downloaded: 68


To cite this article:

Barantsevich ER, Kurushina OV, Akhmadeeva LR, et al. . Bioregulatory drug Newrexan in the treatment of anxiety and dissomnia. Resolution of the Council of Experts (June 8, 2023). S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(7):143‑146. (In Russ.)
https://doi.org/10.17116/jnevro2023123071143

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.